Cytokinetics EVP Callos sells 10K shares at $70

Q: What transactions did CYTK executive Andrew Callos report on this Form 4?

Andrew Callos reported exercising 10,000 stock options at an exercise price of $23.26 per share and selling 10,000 shares of CYTK common stock at $70.24 per share on 2026-08-31.

Q: How many CYTK stock options did Andrew Callos exercise and at what price?

He exercised 10,000 Non-Qualified Stock Options (Right to Buy) at an exercise price of $23.26 per share, converting them into 10,000 shares of CYTOKINETICS INC common stock.

Q: How many CYTK shares did Andrew Callos sell and at what price?

He sold 10,000 shares of CYTK common stock at a reported price of $70.24 per share on 2026-08-31, in a transaction coded as a sale in open market or private transaction.

Q: Were Andrew Callos’s CYTK transactions under a Rule 10b5-1 plan?

Yes. The Form 4 indicates the Rule 10b5-1 checkbox is marked, meaning the reported transactions were effected pursuant to a pre-established trading plan under Rule 10b5-1.

Q: What happened to Andrew Callos’s CYTK stock options after these transactions?

After exercising 10,000 Non-Qualified Stock Options tied to this grant, his reported holdings of that specific option position are 0 shares following the transaction.

CYTOKINETICS INC (CYTK) insider Andrew Callos, EVP and Chief Commercial Officer, exercised 10,000 Non-Qualified Stock Options on 2026-08-31 at an exercise price of $23.26 per share, acquiring 10,000 common shares.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

CYTOKINETICS INC (CYTK) insider Andrew Callos, EVP and Chief Commercial Officer, exercised 10,000 Non-Qualified Stock Options on 2026-08-31 at an exercise price of $23.26 per share, acquiring 10,000 common shares. On the same date, he sold 10,000 common shares at $70.24 per share, leaving 0 options from this grant outstanding. The filing indicates the transactions were made pursuant to a Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Exercise and Sale: 10,000 shares ($470K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Callos Andrew

Role EVP, Chief Commercial Officer

Sold 10,000 shs ($702K)

Approx. gross sale proceeds $702K

Approx. exercise cost $233K

Approx. pre-tax spread $470K

Type	Security	Shares	Price	Value
Exercise	Non-Qualified Stock Option (Right to Buy) ^F1	10,000	$0.00	$0.00
Exercise	Common Stock	10,000	$23.26	$233K
Sale	Common Stock	10,000	$70.24	$702K

Holdings After Transaction: Non-Qualified Stock Option (Right to Buy) — 0 contracts (Direct); Common Stock — 58,555 shares (Direct)

Footnotes (1)

F1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

Key Figures

Options exercised: 10,000 shares Exercise price: $23.26 per share Shares sold: 10,000 shares +2 more

5 metrics

Options exercised 10,000 shares Non-Qualified Stock Option (Right to Buy) exercised on 2026-08-31

Exercise price $23.26 per share Conversion or exercise price of the stock options

Shares sold 10,000 shares Common Stock sale on 2026-08-31

Sale price $70.24 per share Price for the 10,000 Common Stock shares sold

Options remaining from this grant 0 shares Total shares following option exercise transaction

Key Terms

Non-Qualified Stock Option (Right to Buy), Exercise or conversion of derivative security, Sale in open market or private transaction

3 terms

Non-Qualified Stock Option (Right to Buy) financial

"security_title: "Non-Qualified Stock Option (Right to Buy)""

Exercise or conversion of derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

Sale in open market or private transaction financial

"transaction_code_description: "Sale in open market or private transaction""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What transactions did CYTK executive Andrew Callos report on this Form 4?

Andrew Callos reported exercising 10,000 stock options at an exercise price of $23.26 per share and selling 10,000 shares of CYTK common stock at $70.24 per share on 2026-08-31.

How many CYTK stock options did Andrew Callos exercise and at what price?

He exercised 10,000 Non-Qualified Stock Options (Right to Buy) at an exercise price of $23.26 per share, converting them into 10,000 shares of CYTOKINETICS INC common stock.

How many CYTK shares did Andrew Callos sell and at what price?

He sold 10,000 shares of CYTK common stock at a reported price of $70.24 per share on 2026-08-31, in a transaction coded as a sale in open market or private transaction.

Were Andrew Callos’s CYTK transactions under a Rule 10b5-1 plan?

Yes. The Form 4 indicates the Rule 10b5-1 checkbox is marked, meaning the reported transactions were effected pursuant to a pre-established trading plan under Rule 10b5-1.

What happened to Andrew Callos’s CYTK stock options after these transactions?

After exercising 10,000 Non-Qualified Stock Options tied to this grant, his reported holdings of that specific option position are 0 shares following the transaction.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/31/2026 - 04:57 PM EDT Accepted by SEC EDGAR 08/31/2026 - 04:57 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Callos Andrew

(Last)

(First)

(Middle)

350 OYSTER POINT BLVD

(Street)

SOUTH SAN FRANCISCO

CALIFORNIA

94080

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CYTOKINETICS INC [ CYTK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Chief Commercial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/31/2026		M		10,000	A	$23.26	68,555	D
Common Stock	08/31/2026		S		10,000	D	$70.24	58,555	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Non-Qualified Stock Option (Right to Buy)	$23.26	08/31/2026		M			10,000	03/31/2022⁽¹⁾	03/31/2031	Common Stock	10,000	$0	0	D

Explanation of Responses:

1. Stock options will vest over 4 years from the date of the grant, with 1/4th of the shares underlying the reporting person's option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting monthly at a rate of 1/48th of the shares underlying the reporting person's option over the subsequent 36 months, subject to the reporting person's continued employment with the Issuer.

	/s/ John O. Faurescu, attorney-in-fact for Mr. Callos	08/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR